Oral 5lipoxygenaseactivating protein inhibitors

An oral small molecule inhibitor of 5-lipoxygenase-activating protein (FLAP), DG-031, of unknown structure, is in clinical trials with CHD patients. FLAP inhibitors are anticipated to reduce proinflammatory leukotriene mediators such as the potent chemotactic agent, LTB4 (Figure 6). In a 4-week phase II trial in patients with a previous history of MI, DG-031 (250, 500, and 750 mg day" 1 p.o.) at the highest dose reduced serum LTB4 (26%) and MPO (12%) levels as well as soluble intercellular adhesion molecule. As discussed previously, MPO and LTB4 are inflammatory markers associated with a higher risk of CHD. Plasma CRP levels were also reduced at the highest dose, but the response did not reach statistical significance. Accompanying these changes, LDLc levels increased slightly, by 8% with the highest dose.92 These results represent the first demonstration that two key biomarkers of inflammation were reduced following oral dosing with an anti-inflammatory agent in a CHD patient population. It remains to be seen whether these biomarker results translate to a corresponding benefit in actual clinical events, especially given the absence of any profound changes in LDLc, in phase III trials.

Back Pain Relief

Back Pain Relief

This informational eBook will present you with the most recent research and findings available so that you can learn more about Back Pain relief, covering as many bases as possible from A to Z.

Get My Free Ebook


Post a comment